XORTX Files IND with US FDA
March 31, 2022 07:00 ET
|
XORTX Therapeutics Inc.
● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX I...
XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection
March 23, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...
XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study
March 14, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...
XORTX Provides Corporate Update
January 31, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...
XORTX Announces Appointment of Chief Technology Officer
January 20, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...
XORTX to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
January 10, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Jan. 10, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...
XORTX Reports Annual & Special Meeting Results
December 21, 2021 18:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Dec. 21, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...
XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease
December 21, 2021 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Dec. 21, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...
XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients
December 10, 2021 07:01 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Dec. 10, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...
XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners
December 09, 2021 08:04 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Dec. 09, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...